Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

Contact Us

To learn more about Avalanche and our therapies for treating eye-related diseases, contact us.

Avalanche Biotechnologies
1035 O’Brien Drive, Suite A
Menlo Park, CA 94025

Tel: 650-272-6269
Fax: 650-362-1908

Email:

General Inquiry: info@avalanchebiotech.com
Careers: careers@avalanchebiotech.com
Business Development: busdev@avalanchebiotech.com


Or Submit This Contact Form:

Send To:
First Name:*
Last Name:*
Title:
Company Name:*
E-mail Address:*
Phone Number:
Message:*
 

Avalanche Biotechnologies Prices Initial Public Offering of $102.0 Million of Common Stock

July 31, 2014

MENLO PARK, Calif., July 31, 2014 -- Avalanche Biotechnologies, Inc., a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $17.00 per share, before underwriting discounts, commissions and estimated expenses. All of the shares of common stock are being offered by Avalanche. The Company's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading today under the ticker symbol "AAVL".

Read More

Read All Avalanche News